Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
Rhea-AI Summary
Disc Medicine (NASDAQ:IRON) will present Phase 2 RALLY-MF data for investigational DISC-0974 in anemia of myelofibrosis at ASCO 2026 in Chicago, with oral presentation on June 2, 2026.
The abstract (No. 6501) posts online on May 21, 2026; additional, previously unpresented data will be disclosed at the conference. DISC-0974 remains investigational and is not approved for use.
Positive
- None.
Negative
- None.
News Market Reaction – IRON
In the Apr 21 session, IRON declined 3.26%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Phase 3 enrollment | Positive | -3.1% | Completion and expansion of Phase 3 APOLLO enrollment for bitopertin in EPP. |
| Dec 06 | Phase 2 data update | Positive | -1.1% | Positive initial RALLY-MF Phase 2 data for DISC-0974 presented at ASH 2025. |
| Nov 03 | Conference data plan | Positive | -1.8% | Announcement of initial RALLY-MF Phase 2 data presentation at ASH 2025. |
| Sep 30 | NDA submission | Positive | +1.6% | NDA filed for bitopertin in EPP with accelerated approval and priority review plans. |
| Jun 12 | Portfolio data update | Positive | +3.6% | Positive clinical data updates for bitopertin, DISC-0974 and DISC-3405 at EHA 2025. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical and regulatory milestones often draw mixed trading responses, with several positive clinical updates followed by negative or muted price reactions.
Over the past year, Disc Medicine has repeatedly highlighted progress in its hematology pipeline. Key clinical milestones include NDA submission and portfolio-wide positive updates, as well as multiple data readouts and presentations for bitopertin and DISC-0974 across EHA, ASH, and APOLLO. Same-tag clinical trial news has produced an average move of about -0.15%, with several positive data announcements seeing short-term share price declines. Today’s ASCO-focused RALLY-MF update fits into this ongoing stream of clinical visibility events.
Key Terms
myelofibrosis medical
hematologic diseases medical
American Society of Clinical Oncology medical
anti-hemojuvelin antibody medical
hematologic malignancies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of myelofibrosis (MF) in an oral abstract session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago, IL on May 29-June 2, 2026.
“Initial data from the RALLY-MF trial showed anemia response rates that are unprecedented in the hard-to-treat myelofibrosis population,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. “We look forward to bringing a more complete dataset, with additional data from patients receiving transfusions, to the ASCO stage.”
The abstract will be published online on the ASCO conference website on May 21, 2026. Pursuant to Disc Medicine practice, the abstract published will contain previously presented data, and new data and analyses are reserved for presentation at the conference.
DISC-0974 is an investigational agent and is not approved for use as a therapy in any jurisdiction worldwide.
Details of Oral Presentation:
Abstract Number: 6501
Abstract Title: RALLY-MF: Initial efficacy of a phase 2 study of DISC-0974, an anti-hemojuvelin antibody, to treat anemia in myelofibrosis.
Session Type/Title: Oral Abstract Session - Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Session Date and Time: June 2, 2026, 9:45 AM-12:45 PM CDT
Presenting Author: Naseema Gangat, M.B.B.S.
About Disc Medicine
Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding: the projected timelines for the presentation of DISC-0974 data. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Disc’s Annual Report on Form 10-K for the year ended December 31, 2025, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
Christina.tartaglia@precisionaq.com
